FY2024 recorded revenue of RM813.70 million compared to RM704.73 million in FY2023, a growth of 15.5% Profit before tax and profit after tax for FY2024 increased 26.5% and 19.0% respectively year-on-year Duopharma Biotech announces 30.4% increase in total dividend for FY2024 compared to FY2023 Group revenue improves driven by…Read More

You might also be interested in reading Jim Cramer still owns ‘a lot’ of Ether he first bought for an NFT auction.